The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Feb 25

PMID 35204837

Authors

Ying Chen

John Man Tak Chu

Raymond Chuen Chung Chang

Gordon Tin Chun Wong

Affiliations

Soon will be listed here.

Abstract

The functions of the complement system to both innate and adaptive immunity through opsonization, cell lysis, and inflammatory activities are well known. In contrast, the role of complement in the central nervous system (CNS) which extends beyond immunity, is only beginning to be recognized as important to neurodevelopment and neurodegeneration. In addition to protecting the brain against invasive pathogens, appropriate activation of the complement system is pivotal to the maintenance of normal brain function. Moreover, overactivation or dysregulation may cause synaptic dysfunction and promote excessive pro-inflammatory responses. Recent studies have provided insights into the various responses of complement components in different neurological diseases and the regulatory mechanisms involved in their pathophysiology, as well as a glimpse into targeting complement factors as a potential therapeutic modality. However, there remain significant knowledge gaps in the relationship between the complement system and different brain disorders. This review summarizes recent key findings regarding the role of different components of the complement system in health and pathology of the CNS and discusses the therapeutic potential of anti-complement strategies for the treatment of neurodegenerative conditions.

Citing Articles

Secreted IgM deficiency alters the retinal landscape enhancing neurodegeneration associated with aging.

Webster S, Les S, Deleon N, Heck D, Tsuj N, Clemente M Immun Ageing. 2025; 22(1):9.

PMID: 39994686 PMC: 11849284. DOI: 10.1186/s12979-025-00502-2.

Interaction of genetic variants and methylation in transcript-level expression regulation in Alzheimer's disease by multi-omics data analysis.

Han S, Cho S, Choi W, Eilbeck K, Coon H, Nho K BMC Genomics. 2025; 26(1):170.

PMID: 39979805 PMC: 11844006. DOI: 10.1186/s12864-025-11362-x.

The Role of Neuroglia in the Development and Progression of Schizophrenia.

Rawani N, Chan A, Todd K, Baker G, Dursun S Biomolecules. 2025; 15(1).

PMID: 39858403 PMC: 11761573. DOI: 10.3390/biom15010010.

Post-Meningitic Syndrome: Pathophysiology and Consequences of Streptococcal Infections on the Central Nervous System.

Kaddoura R, Abdalbari K, Kadom M, Badla B, Abu Hijleh A, Hanifa M Int J Mol Sci. 2024; 25(20).

PMID: 39456835 PMC: 11507220. DOI: 10.3390/ijms252011053.

The Emerging Role of Immunoglobulins and Complement in the Stimulation of Neuronal Activity and Repair: Not as Simple as We Thought.

Veremeyko T, Barteneva N, Vorobyev I, Ponomarev E Biomolecules. 2024; 14(10).

PMID: 39456256 PMC: 11506258. DOI: 10.3390/biom14101323.

References

Michailidou I, Willems J, Kooi E, van Eden C, Gold S, Geurts J . Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus. Ann Neurol. 2015; 77(6):1007-26. DOI: 10.1002/ana.24398. View

Dalakas M, Alexopoulos H, Spaeth P . Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020; 16(11):601-617. PMC: 7528717. DOI: 10.1038/s41582-020-0400-0. View

Hammond J, Bellizzi M, Ware C, Qiu W, Saminathan P, Li H . Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. Brain Behav Immun. 2020; 87:739-750. PMC: 8698220. DOI: 10.1016/j.bbi.2020.03.004. View

Jacob A, Bao L, Brorson J, Quigg R, Alexander J . C3aR inhibition reduces neurodegeneration in experimental lupus. Lupus. 2009; 19(1):73-82. PMC: 2952506. DOI: 10.1177/0961203309348978. View

Pittock S, Berthele A, Fujihara K, Kim H, Levy M, Palace J . Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(7):614-625. DOI: 10.1056/NEJMoa1900866. View

Gasque P, Singhrao S, Neal J, Gotze O, Morgan B . Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol. 1997; 150(1):31-41. PMC: 1858516. View

Hernandez-Encinas E, Aguilar-Morante D, Cortes-Canteli M, Morales-Garcia J, Gine E, Santos A . CCAAT/enhancer binding protein β directly regulates the expression of the complement component 3 gene in neural cells: implications for the pro-inflammatory effects of this transcription factor. J Neuroinflammation. 2015; 12:14. PMC: 4348118. DOI: 10.1186/s12974-014-0223-2. View

Vukojicic A, Delestree N, Fletcher E, Pagiazitis J, Sankaranarayanan S, Yednock T . The Classical Complement Pathway Mediates Microglia-Dependent Remodeling of Spinal Motor Circuits during Development and in SMA. Cell Rep. 2019; 29(10):3087-3100.e7. PMC: 6937140. DOI: 10.1016/j.celrep.2019.11.013. View

Andoh A, Fujiyama Y, Hata K, Araki Y, Takaya H, Shimada M . Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol. 1999; 118(1):23-9. PMC: 1905403. DOI: 10.1046/j.1365-2249.1999.01038.x. View

10.

Lee J, Kamaruzaman N, Fung J, Taylor S, Turner B, Atkin J . Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2013; 10:119. PMC: 3850877. DOI: 10.1186/1742-2094-10-119. View

11.

OBarr S, Caguioa J, Gruol D, Perkins G, Ember J, Hugli T . Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol. 2001; 166(6):4154-62. DOI: 10.4049/jimmunol.166.6.4154. View

12.

Vesely B, Dufek M, Thon V, Brozman M, Kiralova S, Halaszova T . Interleukin 6 and complement serum level study in Parkinson's disease. J Neural Transm (Vienna). 2018; 125(5):875-881. DOI: 10.1007/s00702-018-1857-5. View

13.

Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A . IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. 2015; 88(2):106-112. DOI: 10.1136/jnnp-2015-311486. View

14.

Wang H, Lee J, Lee K, Woodruff T, Noakes P . Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1 mouse model of amyotrophic lateral sclerosis. Skelet Muscle. 2017; 7(1):10. PMC: 5455206. DOI: 10.1186/s13395-017-0128-8. View

15.

Vasek M, Garber C, Dorsey D, Durrant D, Bollman B, Soung A . A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature. 2016; 534(7608):538-43. PMC: 5452615. DOI: 10.1038/nature18283. View

16.

Tenner A, Stevens B, Woodruff T . New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. Mol Immunol. 2018; 102:3-13. PMC: 6478444. DOI: 10.1016/j.molimm.2018.06.264. View

17.

Lobsiger C, Boillee S, Pozniak C, Khan A, McAlonis-Downes M, Lewcock J . C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc Natl Acad Sci U S A. 2013; 110(46):E4385-92. PMC: 3831990. DOI: 10.1073/pnas.1318309110. View

18.

Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K . Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018; 17(6):519-529. DOI: 10.1016/S1474-4422(18)30114-5. View

19.

Gavriilaki E, Peffault de Latour R, Risitano A . Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood. 2021; 139(25):3571-3582. DOI: 10.1182/blood.2021012860. View

20.

Shi Q, Chowdhury S, Ma R, Le K, Hong S, Caldarone B . Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med. 2017; 9(392). PMC: 6936623. DOI: 10.1126/scitranslmed.aaf6295. View